Notícias e Atividades da Congruence Therapeutics

Fusão, aquisição e financiamento envolvendo Congruence Therapeutics.

• Congruence Therapeutics acaba de anunciar uma arrecadação de fundos de 40 milhões de dólares. (publicado em 25 de março de 2026).

Veja o organograma con seus 21 executivos principais

Biografias mais buscadas da Congruence Therapeutics

• Clarissa Desjardins, Chief Executive Officer
• Nancy Harrison, Director
• Didier Leconte, Director

Recentes movimentos de executivos em Congruence Therapeutics

• Maximilian Ebert antes Director, Computational Molecular Sciences, foi promovido a Vice President, Computational Molecular Sciences  (Notícia publicada em 25 de março de 2026).

Criar um alerta
para seguir os movimentos de executivos da Congruence Therapeutics.

Congruence Therapeutics possui 2.406 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• Oak Hill Bio acaba de anunciar uma arrecadação de fundos de 33 milhões de dólares. (publicado em 4 de junho de 2026).
• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Congruence Therapeutics

• Congruence Announces Participation at the 2026 Bloom Burton & Co. Healthcare Investor Conference
• Congruence Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
• Congruence Announces $39.5M Financing to Advance Portfolio of Small Molecule Correctors into the Clinic
• Congruence Announces First Dosing in Phase 1/1b Clinical Trial of CGX-926, a First-in-Class Oral MC4R Corrector for Genetic Obesity
• Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs
• Congruence Therapeutics to Present Preclinical Characterization of its MC4R Corrector Development Candidate CGX-926 for Genetic Obesity at ObesityWeek 2025
• Congruence Therapeutics Earns "Fierce 15" Distinction for 2025
• Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial
• Congruence Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Advance Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations
• Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit
• View more press releases Close

Redes sociais sobre Congruence Therapeutics

• Congruence Therapeutics na Wikipedia, Google News e Yahoo Finance
• Congruence Therapeutics na LinkedIn, X (Twitter) e YouTube